Insulin Biosimilars: US FDA Hears Wide Range Of Views From Small Set Of Sponsors
US FDA heard a predictably wide range of advice on the appropriate standards for approving biosimilar and interchangeable insulin during a public hearing on the topic. What is surprising is how few sponsors decided to speak out.
